Advertisement
New Zealand markets open in 41 minutes
  • NZX 50

    11,803.28
    -49.52 (-0.42%)
     
  • NZD/USD

    0.5937
    +0.0016 (+0.27%)
     
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • OIL

    83.40
    +1.50 (+1.83%)
     
  • GOLD

    2,335.70
    -10.70 (-0.46%)
     

Is Biogen a Buy?

Is Biogen a Buy?

Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?